Schizophrenia protein may flag hidden heart risk
NCT ID NCT06304233
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study investigates whether a protein called DISC1, known for its role in schizophrenia, is also linked to heart function in people with the condition. Researchers will measure DISC1 levels in blood and use heart imaging (echocardiograms, cardiac MRI, and ECGs) to assess heart structure and performance in 120 adults with schizophrenia. The goal is to see if DISC1 could serve as a biomarker for heart disease, which is more common in this population.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If a link is found, it could point toward a new way to identify heart disease risk in people with schizophrenia, potentially leading to earlier monitoring or treatment.
- What could go wrong
- This is an observational study, not a treatment trial. It may find no clear connection, and results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Jun 2038
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The cohort with schizophrenia will be recruited from outpatient and inpatient population from a single centre. The cohort without mental health diagnosis will be selected from an existing population registered in the HUNT data and biobank and be matched for age (± 2 years) and sex of the patients.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with ICD-10 schizophrenia, schizotypal or delusional disorders (F20 to F29) * Both inpatient and outpatient * Capable of giving informed consent Exclusion Criteria: * Current or previous diagnosis of cancer * Current or previous treatment with chemotherapy * Current pregnancy * Mothers less than 6 months post-partum
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Norwegian University of Science and Technology
Trondheim, Norway
-
St Olavs Hospital, Trondheim University Hospital
Trondheim, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug